Characteristics of Patients with Craniopharyngioma and LongTerm Outcomes of Treatment

Year 2024, Volume: 34 Issue: 2, 60 - 65, 10.06.2024

Hülya Hacişahinoğulları , Gamze Bilik Oyman , Duygu Dölen , M Bilge Bilgiç , Rasim Meral , Gulsah Yalın , Nurdan Gül , Ayşe Kubat Uzum , Özlem Soyluk Selçukbiricik

https://doi.org/10.26650/Tr-ENT.2024.1479029

Abstract

Objective: Craniopharyngioma (CP) is benign, but its treatment is challenging because of its occurrence in a critical area. Hypothalamic-pituitary dysfunction (HPD) is an important complication that is related to tumour itself or to therapy. This study identified the long-term outcomes of CPs.

Material and Methods: Records of 44 patients with CPs followed up at the Istanbul Faculty of Medicine were retrospectively reviewed.

Results: The mean age of 34 patients (M/F: 19/15) at diagnosis was 24±13.3 years. The most common symptoms were headache (60.3%) and visual impairment (45.5%). The tumour was localised in suprasellar region in 76.6%, in sellar-suprasellar in 16.7%, and in the sellar region in 6.7% of the patients. The mean tumour diameter was 32.7±10.4 mm (n: 19). Surgery was the first line of treatment in all patients except one, and 13 patients underwent more than one operation. Ten patients received radiotherapy. The median duration of follow-up was 6.5 years. Anterior pituitary dysfunction was observed in all patients: hypocortisolism in 88.2%, hypothyroidism in 97%, hypogonadism in 88.2%, growth hormone deficiency in 68.2%, and prolactin deficiency in 20.6% of the patients. Diabetes insipidus occurred in 97% of the patients. Recurrence developed in 2 patients (after 5-6 years). At the end of all treatments, 15 patients had residual disease.

Conclusion: The curative treatment of CP is surgery. HPD is associated with increased mortality and morbidity and decreased quality of life. It is essential to protect the hipothalamo-pituitary axis and to choose the best treatment option for each patient.

Keywords

Craniopharyngioma, hormone, pituitary, hormone deficiency, hypothalamus

References

• 1. Parisi JE, Mena H. Nonglial tumours. In: Principles and Practice of Neuropathology. Mosby, St. Louis: Oxford University Press 1993: p.203-66. google scholar
• 2. Ostrom QT, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2014-2018. Neuro Oncol 2021;23:iii1-105. google scholar
• 3. Hölsken A, Sill M, Merkle J, Schweizer L, Buchfelder M, Flitsch J, et al. Adamantinomatous and papillary craniopharyngiomas are characterized by distinct epigenomic as well as mutational and transcriptomic profiles. Acta Neuropathol Commun 2016;4:20. google scholar
• 4. Brastianos PK, Taylor-Weiner A, Manley PE, Jones RT, Dias-Santagata D, Thorner AR, et al. Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. Nat Genet 2014;46(2):161-5. google scholar
• 5. Bunin GR, Surawicz TS, Witman PA, Preston-Martin S, Davis F, Bruner JM. The descriptive epidemiology of craniopharyngioma. J Neurosurg 1998;89(4):547-51. google scholar
• 6. Hoffmann A, Boekhoff S, Gebhardt U, Sterkenburg AS, Daubenbüchel AM, Eveslage M, et al. History before diagnosis in childhood craniopharyngioma: associations with initial presentation and long-term prognosis. Eur J Endocrinol 2015;173(6):853-62. google scholar
• 7. Olsson DS, Andersson E, Bryngelsson IL, Nilsson AG, Johannsson G. Excess mortality and morbidity in patients with craniopharyngioma, especially in patients with childhood-onset: a population-based study in Sweden. J Clin Endocrinol Metab 2015;100(2):467-74. google scholar
• 8. Gan HW, Morillon P, Albanese A, Aquilina K, Chandler C, Chang YC, et al. National UK guidelines for the management of paediatric craniopharyngioma. Lancet Diabetes Endocrinol 2023;11(9):694-706. google scholar
• 9. Clark AJ, Cage TA, Aranda D, Parsa AT, Sun PP, Auguste KI, et al. A systematic review of the results of surgery and radiotherapy on tumor control for pediatric craniopharyngioma. Childs Nerv Syst 2013;29(2):231-8. google scholar
• 10. Caklili M, Uzuner A, Yilmaz E, Duman Ozturk S, Cizmecioglu Jones FM, Balci S, et al. Surgical outcomes and follow-up results of 53 pediatric craniopharyngioma cases: a single-center study. J Neurosurg Pediatr 2023;33(3):223-35. google scholar
• 11. Ordonez-Rubiano EG, Forbes JA, Morgenstern PF, Arko L, Dobri GA, Greenfield JP, et al. Preserve or sacrifice the stalk? Endocrinological outcomes, extent of resection, and recurrence rates following endoscopic endonasal resection of craniopharyngiomas. J Neurosurg 2018:131(4):1163-71. google scholar
• 12. Fric R, König M, Due-T0nnessen BJ, Ramm-Pettersen J, Berg-Johnsen J. Long-term outcome of patients treated for craniopharyngioma: a single center experience. Br J Neurosurg 2023:1-9. google scholar
• 13. Awad M, Butterfield JT, Dhawan S, Tyler MA, Venteicher AS. Prognostic Factors and Treatment Impact on Overall Survival in Adult Craniopharyngioma. World Neurosurg 2023;173:e132-9 google scholar
• 14. Karavitaki N, Brufani C, Warner JT, Adams CBT, Richards P, Ansorge O, et al. Craniopharyngiomas in children and adults: systematic analysis of 121 cases with long-term follow-up. Clin Endocrinol 2005;62(4):397-409. google scholar
• 15. Mende KC, Kellner T, Petersenn S, Honegger J, Evangelista-Zamora R, Droste M, et al. Clinical Situation, Therapy, and Follow-Up of Adult Craniopharyngioma. J Clin Endocrinol Metab 2020;105(1):dgz043. google scholar
• 16. Poretti A, Grotzer MA, Ribi K, Schönle E, Boltshauser E. Outcome of craniopharyngioma in children: long-term complications and quality of life. Dev Med Child Neurol 2004;46(4):220-9. google scholar
• 17. Lo AC, Howard AF, Nichol A, Sidhu K, Abdulsatar F, Hasan H, et al. Long-term outcomes and complications in patients with craniopharyngioma: the British Columbia Cancer Agency experience. Int J Radiat Oncol Biol Phys 2014;88(5):1011-8. google scholar
• 18. Guo Y, Pei L, Li Y, Li C, Gui S, Ni M, et al. Characteristics and factors influencing hypothalamic pituitary dysfunction in patients with craniopharyngioma. Front Endocrinol (Lausanne) 2023;14:1180591. google scholar 19. Kiliç M, Can SM, Özdemir B, Tanik C. Management of Craniopharyngioma. J Craniofac Surg 2019;30(2):e178-83. google scholar
• 20. Caldarelli M, Massimi L, Tamburrini G, Cappa M, Di Rocco C. Long-term results of the surgical treatment of craniopharyngioma: the experience at the Policlinico Gemelli, Catholic University, Rome. Childs Nerv Syst 2005;21(8-9):747-57. google scholar